Collectively, these AR-dependent mechanisms enable prostate cancer cells to resist androgen deprivation and continue to proliferate, highlighting the complexity of CRPC biology and the need for advanced therapeutic strategies that can effectively overcome or bypass AR signaling pathways. The gene discussed is AR; the disease is prostate carcinoma.